Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Clin Gastroenterol Hepatol

Retrieve available abstracts of 365 articles:
HTML format



Single Articles


    May 2024
  1. CAENEPEEL C, Deleu S, Vazquez Castellanos JF, Arnauts K, et al
    RIGOROUS DONOR SELECTION FOR FMT IN ACTIVE ULCERATIVE COLITIS: KEY LESSONS FROM A RANDOMIZED CONTROLLED TRIAL HALTED FOR FUTILITY.
    Clin Gastroenterol Hepatol. 2024 May 22:S1542-3565(24)00492.
    PubMed     Abstract available


  2. GARGALLO-PUYUELO CJ, Ricart E, Iglesias E, de Francisco R, et al
    SEX-RELATED DIFFERENCES IN THE PHENOTYPE AND COURSE OF INFLAMMATORY BOWEL DISEASE: SEXEII STUDY OF ENEIDA.
    Clin Gastroenterol Hepatol. 2024 May 21:S1542-3565(24)00487.
    PubMed     Abstract available


  3. YANG Y, Ludvigsson JF, Forss A, Faucon AL, et al
    Risk of kidney failure in patients with inflammatory bowel disease undergoing colectomy: a nationwide cohort study.
    Clin Gastroenterol Hepatol. 2024 May 20:S1542-3565(24)00484.
    PubMed     Abstract available


  4. ITZKOWITZ SH, Jiang Y, Villagra C, Colombel JF, et al
    Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr: SAPPHIRE Registry.
    Clin Gastroenterol Hepatol. 2024 May 18:S1542-3565(24)00479.
    PubMed     Abstract available


  5. DAI C, Huang YH, Jiang M
    Antibiotic Use and the Risk of Pouchitis after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2024 May 17:S1542-3565(24)00491.
    PubMed    


  6. XUE M, Leibovitzh H, Jingcheng S, Neustaeter A, et al
    Environmental Factors Associated with Risk of Crohn's Disease Development in the CCC-GEM Project.
    Clin Gastroenterol Hepatol. 2024 May 15:S1542-3565(24)00450.
    PubMed     Abstract available


  7. AXELRAD JE, Hashash JG, Itzkowitz SH
    AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients with Malignancy: Commentary.
    Clin Gastroenterol Hepatol. 2024 May 14:S1542-3565(24)00354.
    PubMed     Abstract available


  8. PUDIPEDDI A, Paramsothy S, Kariyawasam V, Paramsothy R, et al
    Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: a Randomized Controlled Trial.
    Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00426.
    PubMed     Abstract available


  9. MOULTON CD, Young AH, Hart AL
    Targeting durable remission of fatigue in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00433.
    PubMed    


  10. AGRAWAL M, Stordal K, Hansen AV, Ostensson M, et al
    Breastfeeding duration is not associated with offspring inflammatory bowel disease risk in three population-based birth cohorts.
    Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00416.
    PubMed     Abstract available


  11. FUMERY M, Caron B, Hebuterne X, Altwegg R, et al
    Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study.
    Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00423.
    PubMed     Abstract available


  12. SANDS BE, D'Haens G, Panaccione R, Regueiro M, et al
    Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
    Clin Gastroenterol Hepatol. 2024 May 7:S1542-3565(24)00405.
    PubMed     Abstract available


  13. ALI S, Pasternak B, Moses J, Suskind DL, et al
    Characterization of Biologic Discontinuation Among Pediatric Patients with Crohn's Disease.
    Clin Gastroenterol Hepatol. 2024 May 7:S1542-3565(24)00406.
    PubMed     Abstract available


  14. ROBLIN X, Moschetti E, Barrau M, Cheifetz AS, et al
    Risankizumab concentration but not IL-22 levels are associated with clinical and biochemical remission in patients with Crohn's disease.
    Clin Gastroenterol Hepatol. 2024 May 3:S1542-3565(24)00402.
    PubMed    


  15. SOFIA MA, Feuerstein JD, Narramore L, Chachu KA, et al
    White Paper: American Gastroenterological Association Position Statement: The Future of IBD Care in the United States-Removing Barriers and Embracing Opportunities.
    Clin Gastroenterol Hepatol. 2024;22:944-955.
    PubMed     Abstract available


  16. SINGH S, Velayos FS, Rubin DT
    Common Instances of Low-value Care in Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2024;22:923-932.
    PubMed     Abstract available


    April 2024
  17. PAPAMICHAEL K, Centritto A, Guillo L, Hier J, et al
    Higher adalimumab concentration is associated with complete fistula healing in patients with perianal fistulizing Crohn's disease.
    Clin Gastroenterol Hepatol. 2024 Apr 29:S1542-3565(24)00397.
    PubMed    


    March 2024
  18. BAGER P, Hvas CL, Dahlerup JF
    Severe Fatigue in Inflammatory Bowel Disease: Dopaminergic Therapy with Modanfinil or Vitamin Therapy with Thiamine.
    Clin Gastroenterol Hepatol. 2024 Mar 18:S1542-3565(24)00283.
    PubMed    


  19. PRENTICE R, Flanagan E, Wright EK, Gibson PR, et al
    Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero.
    Clin Gastroenterol Hepatol. 2024 Mar 14:S1542-3565(24)00252.
    PubMed     Abstract available


  20. PEYRIN-BIROULET L, Panaccione R, Louis E, Atreya R, et al
    Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
    Clin Gastroenterol Hepatol. 2024 Mar 14:S1542-3565(24)00253.
    PubMed     Abstract available


  21. COLOMBEL JF, Hisamatsu T, Atreya R, Bresso F, et al
    Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
    Clin Gastroenterol Hepatol. 2024 Mar 14:S1542-3565(24)00254.
    PubMed     Abstract available


  22. GUPTA A, Peyrin-Biroulet L, Ananthakrishnan AN
    Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis.
    Clin Gastroenterol Hepatol. 2024;22:499-512.
    PubMed     Abstract available


  23. BOYD T, Ananthakrishnan AN
    Geographic Inequities in Access to Phase 3 Clinical Trials for Inflammatory Bowel Disease in the United States.
    Clin Gastroenterol Hepatol. 2024;22:659-661.
    PubMed     Abstract available


    February 2024
  24. AXELRAD JE, Rubin DT
    The Management of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2024 Feb 29:S1542-3565(24)00108.
    PubMed    


  25. WIJNANDS AM, Penning de Vries BBL, Lutgens MWMD, Bakhshi Z, et al
    Dynamic prediction of advanced colorectal neoplasia in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2024 Feb 29:S1542-3565(24)00214.
    PubMed     Abstract available


  26. NARULA N, Wong ECL, Dulai PS, Patel J, et al
    Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated with Low Risk of Disease Progression.
    Clin Gastroenterol Hepatol. 2024 Feb 28:S1542-3565(24)00212.
    PubMed     Abstract available


  27. DUAN R, Zhang C, Li G, Li J, et al
    Antibiotic exposure and risk of new-onset inflammatory bowel disease: a systematic review and dose-response meta-analysis.
    Clin Gastroenterol Hepatol. 2024 Feb 27:S1542-3565(24)00218.
    PubMed     Abstract available


  28. BRENNER EJ, Weaver KN, Zhang X, Kastl AJ, et al
    Long-Term Effectiveness and Durability of COVID-19 Vaccination among Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2024 Feb 16:S1542-3565(24)00203.
    PubMed     Abstract available


  29. POLYDORIDES AD
    Assessment and significance of histologic activity in Crohn disease.
    Clin Gastroenterol Hepatol. 2024 Feb 14:S1542-3565(24)00196.
    PubMed    


  30. KOCHAR B, Ananthakrishnan AN, Ritchie CS
    Pharmacoequity for Older Adults With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2024;22:209-214.
    PubMed    


  31. CONSTANT BD, Albenberg L, Mitchel EB, De Zoeten EF, et al
    Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey.
    Clin Gastroenterol Hepatol. 2024;22:423-426.
    PubMed    


  32. LAPP SL, Bewtra M, Lewis JD
    Yield of Serial Testing for Tuberculosis Exposure in Patients With Inflammatory Bowel Diseases: One Test is Not Enough.
    Clin Gastroenterol Hepatol. 2024;22:420-422.
    PubMed    


  33. CORSETTI M, Ballou S
    Symptom Subgroups Taking Into Account Psychological Burden Predicts Irritable Bowel Syndrome Disease Impact and Burden: A Step Forward?
    Clin Gastroenterol Hepatol. 2024;22:237-240.
    PubMed    


  34. TE GROEN M, Derks M, den Broeder N, Peters C, et al
    Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control Study.
    Clin Gastroenterol Hepatol. 2024;22:357-367.
    PubMed     Abstract available


    January 2024
  35. KEDIA S, Virmani S, Bajaj A, Markandey M, et al
    Coconut water induces clinical remission in mild to moderate ulcerative colitis: double-blind placebo controlled trial.
    Clin Gastroenterol Hepatol. 2024 Jan 24:S1542-3565(24)00088.
    PubMed     Abstract available


  36. AHUJA D, Luo J, Qi Y, Syal G, et al
    Impact of Treatment Response on Risk of Serious Infections in Patients with Crohn's Disease: Secondary Analysis of the PYRAMID Registry.
    Clin Gastroenterol Hepatol. 2024 Jan 10:S1542-3565(24)00047.
    PubMed     Abstract available


  37. MEYER A, Miranda S, Drouin J, Weill A, et al
    Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2024 Jan 8:S1542-3565(24)00010.
    PubMed     Abstract available


  38. MOULTON CD, Young AH, Hart AL
    Modafinil for severe fatigue in inflammatory bowel disease: a prospective case series.
    Clin Gastroenterol Hepatol. 2024 Jan 6:S1542-3565(24)00011.
    PubMed    


  39. VUYYURU SK, Nguyen TM, Murad MH, Narula N, et al
    Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
    Clin Gastroenterol Hepatol. 2024 Jan 5:S1542-3565(24)00003.
    PubMed     Abstract available


  40. KATIBIAN DJ, Solitano V, Polk DB, Nguyen T, et al
    Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2024;22:22-33.
    PubMed     Abstract available


  41. LEMMENS P, Louis E, Van Moerkercke W, Pouillon L, et al
    Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study.
    Clin Gastroenterol Hepatol. 2024;22:154-163.
    PubMed     Abstract available


  42. DE MELLO MK, Freitas Queiroz NS, Papamichael K
    Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?
    Clin Gastroenterol Hepatol. 2024;22:200-201.
    PubMed    


    December 2023
  43. AGRAWAL M, Midya V, Maroli A, Magee J, et al
    Per- and poly-fluoroalkyl substances (PFAS) exposure is associated with later occurrence of inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2023 Dec 26:S1542-3565(23)01055.
    PubMed    


  44. NIGAM GB, Limdi JK, Bate S, Hamdy S, et al
    Fecal Urgency in Ulcerative Colitis: Impact on Quality of Life and Psychological Well-being in Active and Inactive Disease States.
    Clin Gastroenterol Hepatol. 2023 Dec 25:S1542-3565(23)01054.
    PubMed    


  45. ELMASRY S, Ha C
    Evidence-Based Approach to the Management of Mild Crohn's Disease.
    Clin Gastroenterol Hepatol. 2023 Dec 20:S1542-3565(23)00949.
    PubMed    


  46. MCCURDY J, Munir J, Parlow S, Reid J, et al
    Development of an MRI-based prediction model for anti-TNF treatment failure in perianal Crohn's disease: A multicenter study.
    Clin Gastroenterol Hepatol. 2023 Dec 18:S1542-3565(23)01035.
    PubMed     Abstract available


  47. MURTHY SK, Bernstein CN, Nguyen GC, Jairath V, et al
    Interim Analysis of a Trial Evaluating the Utility of Non-Targeted Biopsies for Colorectal Neoplasia Detection in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2023 Dec 18:S1542-3565(23)01036.
    PubMed    


  48. SINGH S, Allegretti J, Nersesova Y, Serra S, et al
    Meeting Summary: AGA Roundtable on Clinical Trial Design in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2023 Dec 16:S1542-3565(23)01033.
    PubMed    


  49. ZINGER A, Choi D, Choi N, Cohen RD, et al
    Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data from a Large Tertiary Center.
    Clin Gastroenterol Hepatol. 2023 Dec 6:S1542-3565(23)00998.
    PubMed    


  50. SOLITANO V, Schaeffer DF, Hogan M, Casteele NV, et al
    Reliability and Responsiveness of Histologic Indices for the Assessment of Crohn's Disease Activity.
    Clin Gastroenterol Hepatol. 2023 Dec 4:S1542-3565(23)00969.
    PubMed     Abstract available


  51. SCHREGEL I, Ramos GP, Ioannou S, Culver E, et al
    Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study.
    Clin Gastroenterol Hepatol. 2023;21:3448-3450.
    PubMed    


    November 2023
  52. ARMUZZI A, Cross RK, Lichtenstein GR, Hou J, et al
    Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
    Clin Gastroenterol Hepatol. 2023 Nov 29:S1542-3565(23)00956.
    PubMed     Abstract available


  53. KAWADA T
    Fecal calprotectin profiles in Crohn's disease: a longitudinal data analysis.
    Clin Gastroenterol Hepatol. 2023 Nov 28:S1542-3565(23)00953.
    PubMed    


  54. MAGRO F, Protic M, De Hertogh G, Chan LS, et al
    Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.
    Clin Gastroenterol Hepatol. 2023 Nov 20:S1542-3565(23)00948.
    PubMed     Abstract available


  55. JAIRATH V, Yarur A, Osterman MT, James A, et al
    ENTERPRET: a randomized controlled trial of vedolizumab dose optimization in patients with ulcerative colitis who have early nonresponse.
    Clin Gastroenterol Hepatol. 2023 Nov 9:S1542-3565(23)00912.
    PubMed     Abstract available


  56. WANG Z, Verstockt B, Sabino J, Ferrante M, et al
    Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study.
    Clin Gastroenterol Hepatol. 2023;21:3188-3190.
    PubMed    


    October 2023
  57. MARILD K, Soderling J, Axelrad J, Halfvarson J, et al
    Histological activity in inflammatory bowel disease and risk of serious infections: A nationwide study.
    Clin Gastroenterol Hepatol. 2023 Oct 30:S1542-3565(23)00855.
    PubMed     Abstract available


  58. SHAH RS, Bachour S, Joseph A, Xiao H, et al
    Real World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn's Disease.
    Clin Gastroenterol Hepatol. 2023 Oct 23:S1542-3565(23)00851.
    PubMed     Abstract available


  59. DIGNASS A, Stremmel W, Horynski M, Poyda O, et al
    Modified-release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-blind, Randomized, Placebo-controlled Trials.
    Clin Gastroenterol Hepatol. 2023 Oct 6:S1542-3565(23)00771.
    PubMed     Abstract available


  60. JANGI S, Hsia K, Zhao N, Kumamoto CA, et al
    Dynamics of the Gut Mycobiome in Patients with Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00762.
    PubMed     Abstract available


  61. A B, M N, B P, M F, et al
    Switching from intra-venous to subcutaneous infliximab is safe and feasible in patients with inflammatory bowel disease suffering from obesity: a post-hoc analysis of the REMSWITCH study.
    Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00766.
    PubMed    


  62. GEEM D, Hercules D, Pelia RS, Venkateswaran S, et al
    Progression of Pediatric Crohn's Disease is Associated with Anti-TNF Timing and BMI Z-Score Normalization.
    Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00757.
    PubMed     Abstract available


  63. ULRICH JA, Habash NW, Ismail YA, Tremaine WJ, et al
    Effectiveness of Hepatitis B Vaccination for Patients With Inflammatory Bowel and Celiac Disease.
    Clin Gastroenterol Hepatol. 2023;21:2901-2907.
    PubMed     Abstract available


  64. BICKSTON SJ, Kaur H
    Higher Rates of Smoking Cessation as a Cause for a Rise in Pouchitis.
    Clin Gastroenterol Hepatol. 2023;21:2988-2989.
    PubMed    


  65. YARUR AJ, McGovern D, Abreu MT, Cheifetz A, et al
    Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab.
    Clin Gastroenterol Hepatol. 2023;21:2908-2917.
    PubMed     Abstract available


    September 2023
  66. WILS P, Jairath V, Sands BE, Reinisch W, et al
    Washout periods in inflammatory bowel disease trials: A systematic literature review and proposed solutions.
    Clin Gastroenterol Hepatol. 2023 Sep 22:S1542-3565(23)00747.
    PubMed    


  67. COLOMBEL JF, Ungaro RC, Sands BE, Siegel CA, et al
    Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER).
    Clin Gastroenterol Hepatol. 2023 Sep 22:S1542-3565(23)00746.
    PubMed     Abstract available


  68. WILSON A, Chande N, Ponich T, Gregor JC, et al
    HLADQA1*05G>A genetic-screening promotes the safe delivery of combination therapy in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2023 Sep 19:S1542-3565(23)00710.
    PubMed    


  69. ODUFALU FD, Loftus EV Jr, Balzora S
    Crohn's Disease: an Equal Opportunity Burden.
    Clin Gastroenterol Hepatol. 2023 Sep 12:S1542-3565(23)00702.
    PubMed    


  70. SOLITANO V, Moschetta A
    Metabolic dysfunction-associated steatotic liver disease (MASLD) in inflammatory bowel disease (IBD): a proposed stepwise approach.
    Clin Gastroenterol Hepatol. 2023 Sep 5:S1542-3565(23)00669.
    PubMed    


  71. CAMILLERI M, Zheng DST
    Cannabinoids and the GI Tract.
    Clin Gastroenterol Hepatol. 2023 Sep 5:S1542-3565(23)00668.
    PubMed     Abstract available


  72. DALAL RS, Kallumkal G, Cabral HJ, Bachour S, et al
    Comparative Effectiveness of Upadacitinib Versus Ustekinumab for Ulcerative Colitis: A Multicenter Retrospective Cohort Study.
    Clin Gastroenterol Hepatol. 2023 Sep 4:S1542-3565(23)00671.
    PubMed    


  73. MCCURDY JD, Stwalley D, Olsen MA, Deepak P, et al
    Comparative effectiveness of biologic therapies in preventing penetrating complications in patients with Crohn's disease.
    Clin Gastroenterol Hepatol. 2023 Sep 4:S1542-3565(23)00664.
    PubMed     Abstract available


  74. IBING S, Cho JH, Bottinger EP, Ungaro RC, et al
    Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
    Clin Gastroenterol Hepatol. 2023;21:2629-2638.
    PubMed     Abstract available


  75. LIMKETKAI BN, Godoy-Brewer G, Parian AM, Noorian S, et al
    Dietary Interventions for the Treatment of Inflammatory Bowel Diseases: An Updated Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2023;21:2508-2525.
    PubMed     Abstract available


  76. HALMA JC, Cristoferi L, Carbone M
    The Time is Ripe for a Randomized Controlled Trial of Oral Vancomycin in Primary Sclerosing Cholangitis.
    Clin Gastroenterol Hepatol. 2023;21:2699-2700.
    PubMed    


  77. ATIA O, Benchimol EI, Ledderman N, Greenfeld S, et al
    Incidence, Management, and Outcomes of Very Early Onset Inflammatory Bowel Diseases and Infantile-Onset Disease: An Epi-IIRN Study.
    Clin Gastroenterol Hepatol. 2023;21:2639-2648.
    PubMed     Abstract available


  78. WANG M, Auerbach A, Oreper SM, Hohmann SF, et al
    Leveraging a New ICD-10 Diagnosis Code to Characterize Hospitalized Patients With Primary Sclerosing Cholangitis.
    Clin Gastroenterol Hepatol. 2023;21:2692-2694.
    PubMed    


  79. MEYER A, Rios P, Drouin J, Weill A, et al
    Maternal Exposure to Anti-TNF or Thiopurines for IBD Does Not Increase Risk of Early-life Malignancy in Children.
    Clin Gastroenterol Hepatol. 2023;21:2679-2681.
    PubMed    


  80. XU L, He B, Sun Y, Li J, et al
    Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-Based Study.
    Clin Gastroenterol Hepatol. 2023 Sep 1:S1542-3565(23)00662.
    PubMed     Abstract available


    August 2023
  81. ANG J, Berggreen P, Couto J, Goh L, et al
    Principles to advance value in inflammatory bowel disease: a collaborative payer-provider framework.
    Clin Gastroenterol Hepatol. 2023 Aug 14:S1542-3565(23)00628.
    PubMed    


  82. ZHOU A, Srinivasan A, Vasudevan A
    Biologic choice should be guided by disease severity not malignancy in patients with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2023 Aug 3:S1542-3565(23)00581.
    PubMed    


  83. DAMAS OM, Maldonado-Contreras A
    Breaking Barriers in Dietary Research: Strategies to Diversify Recruitment in Clinical Studies and Develop Culturally Tailored Diets for Hispanic Communities Living With Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2023;21:2169-2173.
    PubMed    


  84. BUISSON A, Nachury M, Reymond M, Yzet C, et al
    Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.
    Clin Gastroenterol Hepatol. 2023;21:2338-2346.
    PubMed     Abstract available


  85. LOFTUS EV JR, Paul S, Roblin X
    Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too Early to Conclude.
    Clin Gastroenterol Hepatol. 2023;21:2193-2194.
    PubMed    


    July 2023
  86. BRENNER EJ, Zhang X, Long MD, Dubinsky MC, et al
    High Use of Estrogen-based Contraceptives in Young Women with Inflammatory Bowel Disease in the United States.
    Clin Gastroenterol Hepatol. 2023 Jul 21:S1542-3565(23)00541.
    PubMed    


  87. WARD D, Andersen NN, Gortz S, Iversen AT, et al
    Tumour necrosis factor inhibitors in inflammatory bowel disease and risk of immune mediated inflammatory diseases.
    Clin Gastroenterol Hepatol. 2023 Jul 11:S1542-3565(23)00532.
    PubMed     Abstract available


  88. DEEPAK P, Barnes EL, Shaukat A
    Health Disparities in Inflammatory Bowel Disease Care Driven by Rural Versus Urban Residence: Challenges and Potential Solutions.
    Clin Gastroenterol Hepatol. 2023;21:1681-1686.
    PubMed    


  89. BOURGONJE AR, Otten AT
    The Risk of Developing Long COVID in Patients With Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter?
    Clin Gastroenterol Hepatol. 2023;21:1971-1972.
    PubMed    


  90. KHAN N, Mahmud N, Patel M, Sundararajan R, et al
    Incidence of Long COVID and Impact of Medications on the Risk of Developing Long COVID in a Nationwide Cohort of IBD Patients.
    Clin Gastroenterol Hepatol. 2023;21:1960-1962.
    PubMed    


  91. FLUXA D, Stocchi L, Hashash JG
    Rectal Cuff Adenocarcinoma: Rare Complication in Patients with Ileal Pouch-Anal Anastomosis.
    Clin Gastroenterol Hepatol. 2023;21:A41-A42.
    PubMed    


    June 2023
  92. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
    Clin Gastroenterol Hepatol. 2023 Jun 28:S1542-3565(23)00496.
    PubMed     Abstract available


  93. COLOMBEL JF, Sands BE, Gasink C, Yeager B, et al
    Evolution of symptoms after ustekinumab induction therapy in patients with Crohn's disease.
    Clin Gastroenterol Hepatol. 2023 Jun 28:S1542-3565(23)00499.
    PubMed     Abstract available


  94. KHANNA R, Ma C, Hogan M, Zou G, et al
    Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study.
    Clin Gastroenterol Hepatol. 2023 Jun 10:S1542-3565(23)00453.
    PubMed     Abstract available


  95. BEN-HORIN S, Salomon N, Karampekos G, Viazis N, et al
    Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trial.
    Clin Gastroenterol Hepatol. 2023 Jun 9:S1542-3565(23)00445.
    PubMed     Abstract available


  96. HABASH N, Abash I
    Response to the letter to the editor "Measuring of Post-vaccination Hepatitis-B Titers in Patients with Inflammatory Bowel Disease: Thoughts for Further Investigation.".
    Clin Gastroenterol Hepatol. 2023 Jun 9:S1542-3565(23)00455.
    PubMed    


  97. BARNES EL, Long MD, Raffals L, Isaacs K, et al
    Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch.
    Clin Gastroenterol Hepatol. 2023;21:1663-1666.
    PubMed     Abstract available


  98. FLISS ISAKOV N, Kornblum J, Zemel M, Cohen NA, et al
    The Effect of the Crohn's Disease Exclusion Diet on Patients With Pouch Inflammation: An Interventional Pilot Study.
    Clin Gastroenterol Hepatol. 2023;21:1654-1656.
    PubMed     Abstract available


    May 2023
  99. HU W, Liao X, Chen Y
    Is it a case of ileal Crohn's disease?
    Clin Gastroenterol Hepatol. 2023 May 26:S1542-3565(23)00385.
    PubMed    


  100. KARIME C, Hashash JG, Farraye FA
    Measuring of Post-vaccination Hepatitis-B Titers in Patients with Inflammatory Bowel Disease: Thoughts for Further Investigation.
    Clin Gastroenterol Hepatol. 2023 May 13:S1542-3565(23)00348.
    PubMed    


  101. YU A, Ha NB, Shi B, Cheng YW, et al
    Real-World Experience with Tofacitinib Dose De-escalation in Patients with Moderate and Severe Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2023 May 13:S1542-3565(23)00344.
    PubMed     Abstract available


  102. HUTFLESS S, Jasper RA, Chen PH, Joseph S, et al
    Burden of Crohn's Disease in the United States Medicaid Population, 2010 - 2019.
    Clin Gastroenterol Hepatol. 2023 May 13:S1542-3565(23)00346.
    PubMed     Abstract available


  103. NEWMAN KL, Chedid VG, Boden EK
    A Systematic Review of Inflammatory Bowel Disease Epidemiology and Health Outcomes in Sexual and Gender Minority Individuals.
    Clin Gastroenterol Hepatol. 2023;21:1127-1133.
    PubMed    


  104. DAI C, Jiang M, Huang YH
    Appendectomy and Future Risk of Microscopic Colitis: Correlation or Causation?
    Clin Gastroenterol Hepatol. 2023;21:1376-1377.
    PubMed    


  105. DE SOUSA HT, Gullo I, Magro F
    Fibromuscular Expansion in Crohn's Disease Ileal Strictures: An Open Issue.
    Clin Gastroenterol Hepatol. 2023;21:1378-1380.
    PubMed    


  106. KAYAL M, Ungaro RC, Bader G, Colombel JF, et al
    Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data.
    Clin Gastroenterol Hepatol. 2023;21:1348-1350.
    PubMed     Abstract available


    April 2023
  107. OLEN O, Smedby PKE, Erichsen R, Pedersen PL, et al
    Increasing risk of lymphoma over time in Crohn's disease but not in ulcerative colitis: a Scandinavian cohort study.
    Clin Gastroenterol Hepatol. 2023 Apr 13:S1542-3565(23)00268.
    PubMed     Abstract available


  108. BONESCHANSKER L, Ananthakrishnan AN
    Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real world data.
    Clin Gastroenterol Hepatol. 2023 Apr 7:S1542-3565(23)00248.
    PubMed    


  109. SOLITANO V, Facciorusso A, Jess T, Ma C, et al
    Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Clin Gastroenterol Hepatol. 2023;21:907-921.
    PubMed     Abstract available


  110. MENDALL MA
    Obesity and Risk of Crohn's Disease Half the Story.
    Clin Gastroenterol Hepatol. 2023;21:1121-1122.
    PubMed    


    March 2023
  111. WETWITTAYAKHLANG P, Golovics PA, Gonczi L, Lakatos L, et al
    Stable Incidence and Risk Factors of Colorectal Cancer in Ulcerative Colitis:A Population-based Cohort between 1977-2020.
    Clin Gastroenterol Hepatol. 2023 Mar 31:S1542-3565(23)00230.
    PubMed    


  112. CONSTANTINE-COOKE N, Monterrubio-Gomez K, Plevris N, Derikx LAAP, et al
    Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2023 Mar 31:S1542-3565(23)00234.
    PubMed     Abstract available


  113. FITZPATRICK JA, Halmos EP, Machado PP, Gibson PR, et al
    Ultra-processed foods and risk of Crohn's disease: how much is too much?
    Clin Gastroenterol Hepatol. 2023 Mar 24:S1542-3565(23)00217.
    PubMed    


  114. COHEN BL, Lincango E, Holubar SD
    How to Manage Targeted Immune Suppressants (Biologics and Oral Small-molecule Drugs) Perioperatively for Inflammatory Bowel Disease and non-Inflammatory Bowel Disease surgery.
    Clin Gastroenterol Hepatol. 2023 Mar 16:S1542-3565(23)00147.
    PubMed    


  115. CARON B, Ghosh S, Danese S, Peyrin-Biroulet L, et al
    Identifying, understanding and managing fecal urgency in inflammatory bowel diseases.
    Clin Gastroenterol Hepatol. 2023 Mar 9:S1542-3565(23)00172.
    PubMed     Abstract available


  116. FRIEDBERG S, Choi D, Hunold T, Choi NK, et al
    Upadacitinib is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience.
    Clin Gastroenterol Hepatol. 2023 Mar 8:S1542-3565(23)00173.
    PubMed     Abstract available


  117. SAEVIK F
    Prediction of postoperative recurrence in Crohn's disease: where do we go from here?
    Clin Gastroenterol Hepatol. 2023 Mar 3:S1542-3565(23)00170.
    PubMed    


  118. TABATABAVAKILI S, Targownik LE
    Can an Inspiration Around Perspiration Lead to an Innovation In IBD Management?
    Clin Gastroenterol Hepatol. 2023;21:617-618.
    PubMed    


  119. TE GROEN M, Hoentjen F
    Confirming Effectiveness of Endoscopic Colon Cancer Screening in Inflammatory Bowel Disease: The Puzzle Remains Unsolved?
    Clin Gastroenterol Hepatol. 2023;21:850-851.
    PubMed    


  120. VAN DEN BERGHE N, Verstockt B, Vermeire S, Thomas D, et al
    Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2023;21:838-840.
    PubMed    


    February 2023
  121. CHOUNG RS, Petralia F, Torres J, Ungaro RC, et al
    Preclinical Serological Signatures are Associated with Complicated Crohn's Disease Phenotype at Diagnosis.
    Clin Gastroenterol Hepatol. 2023 Feb 12:S1542-3565(23)00100.
    PubMed     Abstract available


  122. KAYAL M, Kohler D, Colombel JF, Dubinsky MC, et al
    Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes.
    Clin Gastroenterol Hepatol. 2023;21:541-542.
    PubMed     Abstract available


  123. POKRYSZKA J, Reinisch S, Primas C, Novacek G, et al
    Induction Efficacy of Upadacitinib in Therapy-Refractory Crohn's Disease: A Retrospective Case Series.
    Clin Gastroenterol Hepatol. 2023;21:532-534.
    PubMed     Abstract available


    January 2023
  124. NARULA N, Chang NH, Mohammad D, Wong ECL, et al
    Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Clin Gastroenterol Hepatol. 2023 Jan 30:S1542-3565(23)00071.
    PubMed     Abstract available


  125. BOUHNIK Y, De Chambrun GP, Lambert J, Nachury M, et al
    Adalimumab in biologic-naive patients with Crohn's disease after resolution of an intra-abdominal abscess: a prospective study from the GETAID.
    Clin Gastroenterol Hepatol. 2023 Jan 30:S1542-3565(23)00072.
    PubMed     Abstract available


  126. HOLMER AK, Luo J, Russ KB, Park S, et al
    Comparative Safety of Biologic Agents in Patients with Inflammatory Bowel Disease with Active or Recent Malignancy: A Multi-Center Cohort Study.
    Clin Gastroenterol Hepatol. 2023 Jan 12:S1542-3565(23)00029.
    PubMed     Abstract available


  127. KAYAL M, Posner H, Spencer E, Colombel JF, et al
    Net Remission Rates with Biologic and Small Molecule Treatment in Ulcerative Colitis: A Reappraisal of the Clinical Trial Data.
    Clin Gastroenterol Hepatol. 2023 Jan 11:S1542-3565(23)00035.
    PubMed    


  128. SANDBORN WJ, Danese S, Leszczyszyn J, Romatowski J, et al
    Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
    Clin Gastroenterol Hepatol. 2023 Jan 6:S1542-3565(23)00007.
    PubMed     Abstract available


  129. MEYER A, Boutron-Ruault MC, Carbonnel F
    Comment on "Food processing and risk of Crohn's disease and ulcerative colitis: A European Prospective Cohort Study": Author's reply.
    Clin Gastroenterol Hepatol. 2023 Jan 4:S1542-3565(23)00005.
    PubMed    


  130. KHAN N, Patel M, Sundararajan R
    Impact of Biologics on SARS-COV-2 Disease Course When Infused Within 2 Weeks of Acquiring the Infection Among IBD Patients.
    Clin Gastroenterol Hepatol. 2023;21:232-233.
    PubMed     Abstract available


  131. DHEYRIAT L, Ward D, Beaugerie L, Jess T, et al
    Risk of Recurrent Acute Arterial Events Associated With Thiopurines and Anti-Tumor Necrosis Factor in Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2023;21:164-172.
    PubMed     Abstract available


  132. KUCHARZIK T, Wilkens R, D'Agostino MA, Maconi G, et al
    Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2023;21:153-163.
    PubMed     Abstract available


  133. NGUYEN NH, Luo J, Paul P, Kim J, et al
    Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
    Clin Gastroenterol Hepatol. 2023;21:173-181.
    PubMed     Abstract available


  134. BARNES EL, Allin KH, Iversen AT, Herfarth HH, et al
    Increasing Incidence of Pouchitis Between 1996 and 2018: A Population-Based Danish Cohort Study.
    Clin Gastroenterol Hepatol. 2023;21:192-199.
    PubMed     Abstract available


    December 2022
  135. VILLUMSEN M, Poulsen G, Andersen NN, Andersson M, et al
    Anti-Tumor Necrosis Factor Treatment does not decrease the Risk of Type 2 Diabetes in Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2022 Dec 22:S1542-3565(22)01178.
    PubMed    


  136. NARULA N, Wong ECL, Pray C, Marshall JK, et al
    Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDs with Inflammatory Bowel Disease: Results from the Prospective Urban Rural Epidemiology (PURE) Study.
    Clin Gastroenterol Hepatol. 2022 Dec 14:S1542-3565(22)01129.
    PubMed     Abstract available


  137. FURFARO F, D'Amico F, Zilli A, Craviotto V, et al
    Non-invasive assessment of postoperative disease recurrence in Crohn's Disease: a multicenter, prospective cohort study on behalf of the IG-IBD.
    Clin Gastroenterol Hepatol. 2022 Dec 12:S1542-3565(22)01131.
    PubMed     Abstract available


  138. GIRI S
    Cross-Sectional Imaging May Serve a Greater Purpose in Postoperative Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:2925.
    PubMed    


  139. BEELEN EMJ, Nieboer D, Arkenbosch JHC, Regueiro MD, et al
    Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials.
    Clin Gastroenterol Hepatol. 2022;20:2741-2752.
    PubMed     Abstract available


  140. MESERVE J, Ma C, Dulai PS, Jairath V, et al
    Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2022;20:2728-2740.
    PubMed     Abstract available


  141. BARNES EL, Kappelman MD, Zhang X, Long MD, et al
    Patients With Pouchitis Demonstrate a Significant Cost Burden in the First Two Years After Ileal Pouch-Anal Anastomosis.
    Clin Gastroenterol Hepatol. 2022;20:2908-2910.
    PubMed     Abstract available


  142. LOFTUS EV JR, Colombel JF, Takeuchi K, Gao X, et al
    Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
    Clin Gastroenterol Hepatol. 2022 Dec 1:S1542-3565(22)01109.
    PubMed     Abstract available


    November 2022
  143. ANDO Y, Yodoshi T, Yoshioka T
    Comment on "Food processing and risk of Crohn's disease and ulcerative colitis: A European Prospective Cohort Study".
    Clin Gastroenterol Hepatol. 2022 Nov 23:S1542-3565(22)01098.
    PubMed    


  144. BUISSON A, Nachury M, Fumery M
    Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Nov 16:S1542-3565(22)01084.
    PubMed    


  145. ALAYO Q, Deepak P
    Reply to Letter to the Editor: Inflammatory Bowel Disease and Incident Acute Arterial Events in the United Kingdom Biobank.
    Clin Gastroenterol Hepatol. 2022 Nov 12. pii: S1542-3565(22)01052.
    PubMed    


  146. PAPAMICHAEL K, Vande Casteele N, Abraham BP, Ritter T, et al
    Prior antibodies to infliximab or adalimumab are related to immunogenicity to vedolizumab in patients with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Nov 10. pii: S1542-3565(22)01053.
    PubMed    


  147. SINGH S, Kim J, Luo J, Paul P, et al
    Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
    Clin Gastroenterol Hepatol. 2022 Nov 4:S1542-3565(22)01018.
    PubMed     Abstract available


  148. MAHMOUD R, Savelkoul EHJ, Jharap B, Oldenburg B, et al
    Anti-TNF withdrawal in inflammatory bowel disease with endoscopic healing and the Risk of Relapse- Authors' response.
    Clin Gastroenterol Hepatol. 2022 Nov 3. pii: S1542-3565(22)01017.
    PubMed    


  149. BALASUBRAMANIAM M, Nandi N, Aswani-Omprakash T, Sebastian S, et al
    Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia.
    Clin Gastroenterol Hepatol. 2022;20:2421-2426.
    PubMed    


  150. CARON B, Abreu MT, Siegel CA, Panaccione R, et al
    IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus.
    Clin Gastroenterol Hepatol. 2022;20:2619-2627.
    PubMed     Abstract available


  151. HANZEL J, Jairath V, Ma C, Guizzetti L, et al
    Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:2598-2606.
    PubMed     Abstract available


  152. LEY D, Leroyer A, Dupont C, Sarter H, et al
    New Therapeutic Strategies Have Changed the Natural History of Pediatric Crohn's Disease: A Two-Decade Population-Based Study.
    Clin Gastroenterol Hepatol. 2022;20:2588-2597.
    PubMed     Abstract available


  153. GIRI S, Angadi S, Jearth V
    Deep Remission in Crohn's Disease: Optional or Quintessential.
    Clin Gastroenterol Hepatol. 2022;20:2654-2655.
    PubMed    


    October 2022
  154. THOMAS AS, Hanauer S, Wang Y
    Immune Checkpoint inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2022 Oct 18. pii: S1542-3565(22)00961.
    PubMed     Abstract available


  155. MEYER A, Dong C, Casagrande C, Chan S, et al
    Food processing and risk of Crohn's disease and ulcerative colitis: A European Prospective Cohort Study.
    Clin Gastroenterol Hepatol. 2022 Oct 12. pii: S1542-3565(22)00929.
    PubMed     Abstract available


  156. CHANG HC, Gau SY
    Inflammatory Bowel Disease and Incident Acute Arterial Events.
    Clin Gastroenterol Hepatol. 2022 Oct 8. pii: S1542-3565(22)00927.
    PubMed    


  157. CHENG D, Kochar BD, Cai T, Ananthakrishnan AN, et al
    Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor alpha Antagonists in Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2022;20:2366-2372.
    PubMed     Abstract available


  158. KOCHAR B, Jylhava J, Soderling J, Ritchie CS, et al
    Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study.
    Clin Gastroenterol Hepatol. 2022;20:2358-2365.
    PubMed     Abstract available


  159. D'HAENS G, Panes J, Louis E, Lacerda A, et al
    Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study.
    Clin Gastroenterol Hepatol. 2022;20:2337-2346.
    PubMed     Abstract available


  160. BACHOUR SP, Shah RS, Lyu R, Nakamura T, et al
    Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:2327-2336.
    PubMed     Abstract available


    September 2022
  161. OKAFOR PN, Dahlen A, Youssef M, Olayode A, et al
    Environmental Pollutants are Associated with Irritable Bowel Syndrome in a Commercially Insured Cohort of California Residents.
    Clin Gastroenterol Hepatol. 2022 Sep 30. pii: S1542-3565(22)00923.
    PubMed     Abstract available


  162. LITTLE RD, Ward MG, Sparrow MP
    Letter to the Editor: can subcutaneous infliximab replace dose-intensified intravenous administration in inflammatory bowel disease?
    Clin Gastroenterol Hepatol. 2022 Sep 22. pii: S1542-3565(22)00913.
    PubMed    


  163. DAI C, Jiang M, Huang YH
    Anti-TNF withdrawal in inflammatory bowel disease with endoscopic healing and the Risk of Relapse.
    Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00914.
    PubMed    


  164. HASHASH JG, Desai A, Kochhar GS, Farraye FA, et al
    Efficacy of Paxlovid and Lagevrio for COVID-19 Infection in patients with Inflammatory Bowel Disease: A Propensity Matched Study.
    Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00908.
    PubMed    


  165. PEYRIN-BIROULET L, Rahier JF, Kirchgesner J, Abitbol V, et al
    I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00916.
    PubMed     Abstract available


  166. ALAYO Q, Loftus EV Jr, Yarur A, Alvarado D, et al
    Inflammatory Bowel Disease is associated with an Increased Risk of Incident Acute Arterial Events: Analysis of the United Kingdom Biobank.
    Clin Gastroenterol Hepatol. 2022 Sep 5. pii: S1542-3565(22)00831.
    PubMed     Abstract available


  167. MAGRO F, Magalhaes D, Patita M, Arroja B, et al
    Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years.
    Clin Gastroenterol Hepatol. 2022;20:2059-2073.
    PubMed     Abstract available


  168. LAHARIE D, D'Haens G, Nachury M, Lambrecht G, et al
    Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
    Clin Gastroenterol Hepatol. 2022;20:2074-2082.
    PubMed     Abstract available


  169. FUDMAN DI, Perez-Reyes AE, Niccum BA, Melmed GY, et al
    Interventions to Decrease Unplanned Healthcare Utilization and Improve Quality of Care in Adults With Inflammatory Bowel Disease: A Systematic Review.
    Clin Gastroenterol Hepatol. 2022;20:1947-1970.
    PubMed     Abstract available


    August 2022
  170. MAHMOUD R, Savelkoul EHJ, Mares W, Goetgebuer R, et al
    Complete endoscopic healing is associated with a lower relapse risk after anti-TNF withdrawal in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Aug 30. pii: S1542-3565(22)00820.
    PubMed     Abstract available


  171. WHALEY KG, Xiong Y, Karns R, Hyams JS, et al
    MULTICENTER COHORT STUDY OF INFLIXIMAB PHARMACOKINETICS AND THERAPY RESPONSE IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS.
    Clin Gastroenterol Hepatol. 2022 Aug 25. pii: S1542-3565(22)00812.
    PubMed     Abstract available


  172. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2022 Aug 24. pii: S1542-3565(22)00811.
    PubMed     Abstract available


  173. STRAATMIJER T, van der Meulen AE, Duijvestein M
    Comparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons? Authors' reply.
    Clin Gastroenterol Hepatol. 2022 Aug 9. pii: S1542-3565(22)00739.
    PubMed    


  174. SAUK JS, Ryu HJ, Labus JS, Khandadash A, et al
    High Perceived Stress is Associated with Increased Risk of Ulcerative Colitis Clinical Flares.
    Clin Gastroenterol Hepatol. 2022 Aug 8. pii: S1542-3565(22)00721.
    PubMed     Abstract available


  175. DULAI PS, Feagan BG, Sands BE, Chen J, et al
    Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2022 Aug 4. pii: S1542-3565(22)00718.
    PubMed     Abstract available


  176. LONG MD, Weaver KN, Zhang X, Chun K, et al
    Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2022;20:1881-1883.
    PubMed     Abstract available


  177. OLLECH JE, Bannon L, Maharshak N, Bar N, et al
    Fecal Calprotectin Is Increased in Pouchitis and Progressively Increases With More Severe Endoscopic and Histologic Disease.
    Clin Gastroenterol Hepatol. 2022;20:1839-1846.
    PubMed     Abstract available


  178. KEEFER L, Gorbenko K, Siganporia T, Manning L, et al
    Resilience-based Integrated IBD Care Is Associated With Reductions in Health Care Use and Opioids.
    Clin Gastroenterol Hepatol. 2022;20:1831-1838.
    PubMed     Abstract available


  179. MA C
    To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:1668-1670.
    PubMed    


  180. PAUWELS RWM, van der Woude CJ, Nieboer D, Steyerberg EW, et al
    Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.
    Clin Gastroenterol Hepatol. 2022;20:1671-1686.
    PubMed     Abstract available


    July 2022
  181. GUBATAN J, Barber GE, Nielsen OH, Juhl CB, et al
    Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-Analysis.
    Clin Gastroenterol Hepatol. 2022 Jul 20. pii: S1542-3565(22)00675.
    PubMed     Abstract available


  182. BUIE MJ, Quan BKin J, Windsor JW, Coward S, et al
    Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21(st) Century: A Systematic Review with Temporal Analyses.
    Clin Gastroenterol Hepatol. 2022 Jul 18. pii: S1542-3565(22)00670.
    PubMed     Abstract available


  183. ALSOUD D, Verstockt B, Vermeire S
    Comparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons?
    Clin Gastroenterol Hepatol. 2022 Jul 15. pii: S1542-3565(22)00656.
    PubMed    


  184. JENA A, James D, Singh AK, Dutta U, et al
    Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.
    Clin Gastroenterol Hepatol. 2022;20:1456-1479.
    PubMed     Abstract available


  185. AKIYAMA S, Rodriguez TG, Rubin DT
    Stratifying Risks of Ileal Pouch Outcomes.
    Clin Gastroenterol Hepatol. 2022;20:1620-1621.
    PubMed    


  186. NARULA N, Wong ECL, Dulai PS, Sengupta NK, et al
    Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:1579-1587.
    PubMed     Abstract available


  187. BATTAT R, Sandborn WJ
    Advances in the Comprehensive Management of Postoperative Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:1436-1449.
    PubMed     Abstract available


    June 2022
  188. RIVIERE P, Bislenghi G, Vermeire S, Domenech E, et al
    Postoperative Crohn's Disease Recurrence: Time to Adapt Endoscopic Recurrence Scores to the Leading Surgical Techniques.
    Clin Gastroenterol Hepatol. 2022;20:1201-1204.
    PubMed    


  189. KOCHAR B, Pate V, Kappelman MD, Long MD, et al
    Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
    Clin Gastroenterol Hepatol. 2022;20:1299-1305.
    PubMed     Abstract available


  190. LIU Q, Zhang X, Ko HM, Stocker D, et al
    Constrictive and Hypertrophic Strictures in Ileal Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:e1292-e1304.
    PubMed     Abstract available


  191. DE GREGORIO M, Lee T, Krishnaprasad K, Amos G, et al
    Higher Anti-tumor Necrosis Factor-alpha Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas.
    Clin Gastroenterol Hepatol. 2022;20:1306-1314.
    PubMed     Abstract available


  192. FINK M, Simons M, Tomasino K, Pandit A, et al
    When Is Patient Behavior Indicative of Avoidant Restrictive Food Intake Disorder (ARFID) Vs Reasonable Response to Digestive Disease?
    Clin Gastroenterol Hepatol. 2022;20:1241-1250.
    PubMed     Abstract available


    May 2022
  193. STRAATMIJER T, Biemans VB, Visschedijk M, Hoentjen F, et al
    Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF experienced ulcerative colitis patients: a nationwide Dutch Registry study.
    Clin Gastroenterol Hepatol. 2022 May 26. pii: S1542-3565(22)00510.
    PubMed     Abstract available


  194. OZEKI K, Tanida S, Kataoka H
    Aseptic abscess syndrome with ulcerative colitis and pyoderma gangrenosum.
    Clin Gastroenterol Hepatol. 2022 May 25. pii: S1542-3565(22)00512.
    PubMed    


  195. SCHWARTZ DA, Peyrin-Biroulet L, Lasch K, Adsul S, et al
    Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study.
    Clin Gastroenterol Hepatol. 2022;20:1059-1067.
    PubMed     Abstract available


  196. DULAI PS, Wong ECL, Reinisch W, Narula N, et al
    Clinical Decision Support Tool for Infliximab in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:e1192-e1195.
    PubMed     Abstract available


  197. AHN HJ, Kim YJ, Lee HS, Park JH, et al
    High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2022;20:e1022-e1039.
    PubMed     Abstract available


  198. KAWAMOTO A, Takenaka K, Hibiya S, Ohtsuka K, et al
    Serum Leucine-Rich alpha2 Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:e1196-e1200.
    PubMed     Abstract available


  199. SCHAEFER M, Laurent V, Grandmougin A, Vuitton L, et al
    A Magnetic Resonance Imaging Index to Predict Crohn's Disease Postoperative Recurrence: The MONITOR Index.
    Clin Gastroenterol Hepatol. 2022;20:e1040-e1049.
    PubMed     Abstract available


  200. HUANG X, Li X
    Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:e1216.
    PubMed    


  201. QUINN KP, Urquhart SA, Janssens LP, Lennon RJ, et al
    Primary Sclerosing Cholangitis-Associated Pouchitis: A Distinct Clinical Phenotype.
    Clin Gastroenterol Hepatol. 2022;20:e964-e973.
    PubMed     Abstract available


    April 2022
  202. COHEN NA, Choi D, Choden T, Cleveland NK, et al
    Ozanimod in the Treatment of Ulcerative Colitis: Initial Real World Data from A Large Tertiary Center.
    Clin Gastroenterol Hepatol. 2022 Apr 2. pii: S1542-3565(22)00310.
    PubMed    


  203. STEINER CA, Berinstein JA, Louissaint J, Higgins PDR, et al
    Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review.
    Clin Gastroenterol Hepatol. 2022;20:817-846.
    PubMed     Abstract available


  204. ALLOCCA M, Craviotto V, Bonovas S, Furfaro F, et al
    Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study.
    Clin Gastroenterol Hepatol. 2022;20:e723-e740.
    PubMed     Abstract available


  205. CALABRESE E, Rispo A, Zorzi F, De Cristofaro E, et al
    Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study.
    Clin Gastroenterol Hepatol. 2022;20:e711-e722.
    PubMed     Abstract available


  206. BLACKWELL J, Saxena S, Jayasooriya N, Petersen I, et al
    Stoma Formation in Crohn's Disease and the Likelihood of Antidepressant Use: A Population-Based Cohort Study.
    Clin Gastroenterol Hepatol. 2022;20:e703-e710.
    PubMed     Abstract available


    March 2022
  207. SONNENBERG A, Turner KO, Saboorian H, Singhal A, et al
    The Occurrence of Gastritis in Microscopic Colitis and Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2022 Mar 23. pii: S1542-3565(22)00294.
    PubMed    


  208. ANYANE-YEBOA A, Quezada S, Rubin DT, Balzora S, et al
    The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2022 Mar 17. pii: S1542-3565(22)00285.
    PubMed     Abstract available


  209. VEYRARD P, Pellet G, Laharie D, Nachury M, et al
    Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis.
    Clin Gastroenterol Hepatol. 2022 Mar 17. pii: S1542-3565(22)00282.
    PubMed    


  210. DANESE S, Sands BE, Abreu MT, O'Brien CD, et al
    Early symptomatic improvement after ustekinumab therapy in patients with ulcerative colitis: 16-week data from the UNIFI trial.
    Clin Gastroenterol Hepatol. 2022 Mar 8. pii: S1542-3565(22)00207.
    PubMed     Abstract available


  211. BEN-HORIN S, Har-Noy O, Katsanos KH, Roblin X, et al
    Corticosteroids and 5-ASA versus corticosteroids for acute severe ulcerative colitis: A randomized controlled trial.
    Clin Gastroenterol Hepatol. 2022 Mar 7. pii: S1542-3565(22)00213.
    PubMed     Abstract available


  212. TARGOWNIK LE, Bernstein CN, Benchimol EI, Kaplan GG, et al
    Earlier Anti-TNF Initiation Leads to Long Term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2022 Mar 2. pii: S1542-3565(22)00147.
    PubMed     Abstract available


  213. PUDIPEDDI A, Paramsothy S, Leong RW
    Combination Therapy of Immunomodulators With Non-Anti-Tumor Necrosis Factor Agents in Inflammatory Bowel Disease: Need More Evidence?
    Clin Gastroenterol Hepatol. 2022;20:e640-e641.
    PubMed    


  214. ATIA O, Asayag N, Focht G, Lujan R, et al
    Perianal Crohn's Disease Is Associated With Poor Disease Outcome: A Nationwide Study From the epiIIRN Cohort.
    Clin Gastroenterol Hepatol. 2022;20:e484-e495.
    PubMed     Abstract available


  215. SANDBORN WJ, Rebuck R, Wang Y, Zou B, et al
    Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
    Clin Gastroenterol Hepatol. 2022;20:578-590.
    PubMed     Abstract available


  216. GUILLO L, Rabaud C, Choy EH, D'Amico F, et al
    Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide.
    Clin Gastroenterol Hepatol. 2022;20:481-490.
    PubMed     Abstract available


    February 2022
  217. KIM HS, Hernaez R, Sansgiry S, Waljee AK, et al
    Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2022 Feb 28. pii: S1542-3565(22)00205.
    PubMed     Abstract available


  218. RODRIGUEZ-DUQUE JC, Calleja JL, Iruzubieta P, Hernandez-Conde M, et al
    Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors.
    Clin Gastroenterol Hepatol. 2022 Feb 3. pii: S1542-3565(22)00093.
    PubMed     Abstract available


  219. HUANG X, Li X
    Predictive Value of Bowel Ultrasound in Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:e345-e346.
    PubMed    


  220. HUNTER JO
    Dietary Treatment of Crohn's Disease in Adults.
    Clin Gastroenterol Hepatol. 2022;20:e343.
    PubMed    


  221. NG A
    Maintenance Therapy in Crohn's Disease: Does the Drug Matter?
    Clin Gastroenterol Hepatol. 2022;20:472-473.
    PubMed    


  222. KAYAL M, Ungaro RC, Colombel JF
    The Chicago Classification of Pouchitis: An Important Step Toward a Needed Consensus.
    Clin Gastroenterol Hepatol. 2022;20:281-282.
    PubMed    


  223. LUCAS UEMURA K, Sousa Freitas Queiroz N, Lees CW
    What is the Real Impact of Corticosteroids in the Contemporary Treatment of Crohn's Disease?
    Clin Gastroenterol Hepatol. 2022;20:468-469.
    PubMed    


  224. SINGH S, Heien HC, Herrin J, Dulai PS, et al
    Comparative Risk of Serious Infections With Tumor Necrosis Factor alpha Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2022;20:e74-e88.
    PubMed     Abstract available


  225. VANDE CASTEELE N, Abreu MT, Flier S, Papamichael K, et al
    Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
    Clin Gastroenterol Hepatol. 2022;20:465-467.
    PubMed     Abstract available


  226. BROCHARD C, Rabilloud ML, Hamonic S, Bajeux E, et al
    Natural History of Perianal Crohn's Disease: Long-term Follow-up of a Population-Based Cohort.
    Clin Gastroenterol Hepatol. 2022;20:e102-e110.
    PubMed     Abstract available


  227. KAMBOJ AK, Kane SV, Leggett CL
    Crohn's Disease of the Esophagus.
    Clin Gastroenterol Hepatol. 2022;20:A15-A16.
    PubMed    


    January 2022
  228. MAHMOUD R, Schultheiss JPD, Louwers JM, van der Kaaij MT, et al
    Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2022 Jan 28. pii: S1542-3565(22)00073.
    PubMed     Abstract available


  229. LOPES EW, Lochhead P, Burke KE, Richter JM, et al
    Risk Factors for Incident Inflammatory Bowel Disease According to Disease Phenotype.
    Clin Gastroenterol Hepatol. 2022 Jan 11. pii: S1542-3565(22)00026.
    PubMed     Abstract available


  230. FREY S, Chowdhury R, Connolly CM, Werbel WA, et al
    Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2022 Jan 5. pii: S1542-3565(22)00003.
    PubMed    


  231. KAWADA T
    Stoma Formation and Antidepressant Use in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:245-246.
    PubMed    


  232. HANZEL J, Ma C, Zou G, Singh S, et al
    Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT.
    Clin Gastroenterol Hepatol. 2022;20:236-238.
    PubMed     Abstract available


  233. HASHASH JG, Knisely MR, Germain A, McAuliff K, et al
    Brief Behavioral Therapy and Bupropion for Sleep and Fatigue in Young Adults With Crohn's Disease: An Exploratory Open Trial Study.
    Clin Gastroenterol Hepatol. 2022;20:96-104.
    PubMed     Abstract available


  234. ALMUHAIDB A, Sina J, Chen CH
    Unusual Presentation of a Crohn's Disease Patient: Not Your Typical Flare.
    Clin Gastroenterol Hepatol. 2022;20:e5-e6.
    PubMed    


    December 2021
  235. KAKUTA Y, Shirai T, McGovern DPB, Braun J, et al
    Novel diagnostic autoantibodies against Endothelial Protein C Receptor in patients with ulcerative colitis.
    Clin Gastroenterol Hepatol. 2021 Dec 28. pii: S1542-3565(21)01359.
    PubMed    


  236. LEV-TZION R, Focht G, Lujan R, Mendelovici A, et al
    COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation.
    Clin Gastroenterol Hepatol. 2021 Dec 23. pii: S1542-3565(21)01350.
    PubMed     Abstract available


  237. CHARILAOU P, Tricarico C, Battat R, Scherl EJ, et al
    Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS CoV-2 Vaccination.
    Clin Gastroenterol Hepatol. 2021 Dec 8. pii: S1542-3565(21)01301.
    PubMed    


  238. SCHELL TL, Richard LJ, Tippins K, Russ RK, et al
    High but Inequitable COVID-19 Vaccine Uptake Among Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Dec 8. pii: S1542-3565(21)01308.
    PubMed    


  239. BAMIAS G, Cominelli F
    Exploring the Early Phase of Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:2469-2480.
    PubMed     Abstract available


  240. SHAFER LA, Sofia MA, Rubin DT, Steinhart AH, et al
    An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI.
    Clin Gastroenterol Hepatol. 2021;19:2524-2531.
    PubMed     Abstract available


    November 2021
  241. LUKIN DJ, Funez-dePagnier G, Lima S, Lai D, et al
    No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.
    Clin Gastroenterol Hepatol. 2021;19:2312-2314.
    PubMed    


  242. DEBNATH P, Rathi P
    Treat to Target in Patients with Ileocolonic Crohn's Disease: Endoscopic Remission or Histologic Healing?
    Clin Gastroenterol Hepatol. 2021;19:2452.
    PubMed    


  243. COHEN-MEKELBURG S, Yu X, Costa D, Hofer TP, et al
    Variation in Provider Connectedness Associates With Outcomes of Inflammatory Bowel Diseases in an Analysis of Data From a National Health System.
    Clin Gastroenterol Hepatol. 2021;19:2302-2311.
    PubMed     Abstract available


    October 2021
  244. KUMAR R, Zaghiyan K, Ha C
    Lower Surgical Risks in "Contemporary" IBD Cohorts: A Reflection of Better Quality of Care or Statistics?
    Clin Gastroenterol Hepatol. 2021;19:2029-2030.
    PubMed    


  245. DEBNATH P, Rathi P
    Outcomes Related to Mucosal Healing in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:2214.
    PubMed    


  246. FENSTER M, Alayo QA, Khatiwada A, Wang W, et al
    Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium.
    Clin Gastroenterol Hepatol. 2021;19:2207-2209.
    PubMed     Abstract available


  247. QIAN AS, Nguyen NH, Elia J, Ohno-Machado L, et al
    Frailty Is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:2054-2063.
    PubMed     Abstract available


  248. SCOTT FI, Hans AK, Gerich ME, Fennimore B, et al
    Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:2082-2092.
    PubMed     Abstract available


  249. SOH H, Lee HJ, Han K, Park S, et al
    Atopic Diseases Are Associated With Development of Inflammatory Bowel Diseases in Korea: A Nationwide Population-based Study.
    Clin Gastroenterol Hepatol. 2021;19:2072-2081.
    PubMed     Abstract available


    September 2021
  250. GUPTA A, Yu A, Peyrin-Biroulet L, Ananthakrishnan AN, et al
    Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2021;19:1800-1813.
    PubMed     Abstract available


  251. PLEVRIS N, Fulforth J, Lyons M, Siakavellas SI, et al
    Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:1835-1844.
    PubMed     Abstract available


  252. HAMDEH S, Micic D, Hanauer S
    Drug-Induced Colitis.
    Clin Gastroenterol Hepatol. 2021;19:1759-1779.
    PubMed     Abstract available


    August 2021
  253. PUGLIESE D, Privitera G, Schepis T, Larosa L, et al
    Drug-related pneumonitis in patients receiving Vedolizumab therapy for Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Aug 31. pii: S1542-3565(21)00921.
    PubMed    


  254. LO CH, Khandpur N, Rossato SL, Lochhead P, et al
    Ultra-processed foods and risk of Crohn's disease and ulcerative colitis: a prospective cohort study.
    Clin Gastroenterol Hepatol. 2021 Aug 27. pii: S1542-3565(21)00911.
    PubMed     Abstract available


  255. BERINSTEIN JA, Cohen-Mekelburg SA, Greenberg GM, Wray D, et al
    A Care Coordination Intervention Improves Symptoms but not Charges in High-Risk Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Aug 27. pii: S1542-3565(21)00914.
    PubMed     Abstract available


  256. WONG ECL, Colombel JF, Riddell R, Marshall JK, et al
    Epithelial Neutrophilic Infiltrate - The Rising Star in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021 Aug 20. pii: S1542-3565(21)00904.
    PubMed    


  257. SASSON AN, Sheehan G, Yu A, Gupta A, et al
    Yield and Predictors of surveillance colonoscopies in older adults with long-standing ulcerative colitis.
    Clin Gastroenterol Hepatol. 2021 Aug 20. pii: S1542-3565(21)00899.
    PubMed     Abstract available


  258. D'SILVA A, Fox DE, Raman M
    This Letter to the Editor is in response to: Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease/Dr. Maitreyi Raman.
    Clin Gastroenterol Hepatol. 2021 Aug 16. pii: S1542-3565(21)00874.
    PubMed    


  259. YELENCICH E, Truong E, Widaman AM, Pignotti G, et al
    Avoidant Restrictive Food Intake Disorder Prevalent among Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Aug 10. pii: S1542-3565(21)00864.
    PubMed     Abstract available


  260. ESTEVINHO MM, Magro F
    Epithelial neutrophilic infiltrate - the rising star in ulcerative colitis.
    Clin Gastroenterol Hepatol. 2021 Aug 5. pii: S1542-3565(21)00835.
    PubMed    


  261. DALAL RS, McClure E, Marcus J, Winter RW, et al
    COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:1730-1732.
    PubMed     Abstract available


  262. YANAI H, Goren I, Godny L, Maharshak N, et al
    Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable.
    Clin Gastroenterol Hepatol. 2021;19:1564-1572.
    PubMed     Abstract available


  263. DE BRUYN JR, Bossuyt P, Ferrante M, West RL, et al
    High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial.
    Clin Gastroenterol Hepatol. 2021;19:1573-1582.
    PubMed     Abstract available


    July 2021
  264. RUDRA S, Shaul E, Conrad M, Patel T, et al
    Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset- Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Jul 27. pii: S1542-3565(21)00822.
    PubMed    


  265. NARULA N, Wong ECL, Marshall JK, Colombel JF, et al
    Comparative Efficacy for Infliximab vs. Vedolizumab in Biologic Naive Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021 Jul 27. pii: S1542-3565(21)00820.
    PubMed     Abstract available


  266. DAI C, Jiang M, Huang YH
    Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Jul 21. pii: S1542-3565(21)00759.
    PubMed    


  267. MEYER A, Taine M, Drouin J, Weill A, et al
    Serious infections in children born to mothers with inflammatory bowel disease with in utero exposure to thiopurines and anti-TNF.
    Clin Gastroenterol Hepatol. 2021 Jul 20. pii: S1542-3565(21)00760.
    PubMed     Abstract available


  268. KHAN N, Wang L, Trivedi C, Pernes T, et al
    Efficacy of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Jul 15. pii: S1542-3565(21)00754.
    PubMed     Abstract available


  269. CHAN SSM, Chen Y, Casey K, Olen O, et al
    Obesity is associated with increased risk of Crohn's disease, but not ulcerative colitis: A pooled analysis of five prospective cohort studies.
    Clin Gastroenterol Hepatol. 2021 Jul 6. pii: S1542-3565(21)00720.
    PubMed     Abstract available


  270. NARULA N, Wong ECL, Colombel JF, Riddell R, et al
    Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021 Jul 3. pii: S1542-3565(21)00716.
    PubMed     Abstract available


  271. RODRIGUEZ-LAGO I, Barreiro-de Acosta M
    Look at Both Sides of the Coin in Determining Risk of Complicated Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:1503-1504.
    PubMed    


  272. SEDANO R, Guizzetti L, McDonald C, Jairath V, et al
    Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing.
    Clin Gastroenterol Hepatol. 2021;19:1497-1498.
    PubMed     Abstract available


  273. KAYAL M, Lambin T, Plietz M, Rizvi A, et al
    Recycling of Precolectomy Anti-Tumor Necrosis Factor Agents in Chronic Pouch Inflammation Is Associated With Treatment Failure.
    Clin Gastroenterol Hepatol. 2021;19:1491-1493.
    PubMed     Abstract available


  274. HU A, Kotze PG, Burgevin A, Tan W, et al
    Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Clin Gastroenterol Hepatol. 2021;19:1366-1376.
    PubMed     Abstract available


  275. NGUYEN NH, Khera R, Ohno-Machado L, Sandborn WJ, et al
    Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:1377-1386.
    PubMed     Abstract available


  276. MILLIEN V, Abrams D, Khalaf N
    Not All Terminal Ileitis Is Crohn's Disease: Intestinal Tuberculosis Causing Small Bowel Obstruction.
    Clin Gastroenterol Hepatol. 2021;19:e71.
    PubMed    


    June 2021
  277. D'SILVA A, Fox DE, Nasser Y, Vallance JK, et al
    Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease: A Systematic Review with Meta-analysis.
    Clin Gastroenterol Hepatol. 2021 Jun 30. pii: S1542-3565(21)00698.
    PubMed     Abstract available


  278. ASSCHER VER, Waars SN, van der Meulen-de Jong AE, Stuyt RJL, et al
    Deficits in geriatric assessment associate with disease activity and -burden in older patients with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2021 Jun 18. pii: S1542-3565(21)00643.
    PubMed     Abstract available


  279. CASSINOTTI A, Corona A, Duca P, Nebuloni M, et al
    NON INVASIVE MONITORING AFTER AZATHIOPRINE WITHDRAWAL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN DEEP REMISSION.
    Clin Gastroenterol Hepatol. 2021 Jun 14. pii: S1542-3565(21)00642.
    PubMed     Abstract available


  280. DANESE S, Klopocka M, Scherl EJ, Romatowski J, et al
    Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study [102/120 characters including spaces].
    Clin Gastroenterol Hepatol. 2021 Jun 11. pii: S1542-3565(21)00614.
    PubMed     Abstract available


  281. AGRAWAL M, Brenner EJ, Yan Mak JW, Zhang X, et al
    COVID-19 outcomes among racial and ethnic minority individuals with inflammatory bowel disease in the United States.
    Clin Gastroenterol Hepatol. 2021 Jun 2. pii: S1542-3565(21)00599.
    PubMed    


  282. FAHAD H, Dulai PS, Shen B, Kochhar GS, et al
    Hyperbaric Oxygen Therapy Is Effective in the Treatment of Inflammatory and Fistulizing Pouch Complications.
    Clin Gastroenterol Hepatol. 2021;19:1288-1291.
    PubMed     Abstract available


  283. BRAGA NETO MB, Ramos GP, Loftus EV Jr, Faubion WA, et al
    Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series.
    Clin Gastroenterol Hepatol. 2021;19:1285-1287.
    PubMed     Abstract available


  284. POUILLON L, Remen T, Amicone C, Louis E, et al
    Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers.
    Clin Gastroenterol Hepatol. 2021;19:1218-1225.
    PubMed     Abstract available


  285. VANDE CASTEELE N, Jairath V, Jeyarajah J, Dulai PS, et al
    Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab.
    Clin Gastroenterol Hepatol. 2021;19:1209-1217.
    PubMed     Abstract available


  286. HU AB, Tan W, Deshpande V, Ananthakrishnan AN, et al
    Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission.
    Clin Gastroenterol Hepatol. 2021;19:1226-1233.
    PubMed     Abstract available


  287. LAGRANGE J, Lacolley P, Wahl D, Peyrin-Biroulet L, et al
    Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:1088-1097.
    PubMed     Abstract available


    May 2021
  288. TROELSEN FS, Sorensen HT, Crockett SD, Pedersen L, et al
    Characteristics and survival of patients with inflammatory bowel disease and post-colonoscopy colorectal cancers.
    Clin Gastroenterol Hepatol. 2021 May 26. pii: S1542-3565(21)00577.
    PubMed     Abstract available


  289. BERINSTEIN JA, Sheehan J, Dias M, Berinstein EM, et al
    Tofacitinib for Biologic-Experienced Hospitalized Patients with Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
    Clin Gastroenterol Hepatol. 2021 May 25. pii: S1542-3565(21)00576.
    PubMed     Abstract available


  290. KAYAL M, Ungaro RC, Riggs A, Kamal K, et al
    Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis is Associated with Significant Disability.
    Clin Gastroenterol Hepatol. 2021 May 22. pii: S1542-3565(21)00571.
    PubMed     Abstract available


  291. AHMED W, Scott FI
    Closing the gap: the real-world risk of serious infections with vedolizumab in comparison to anti-TNF therapy in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2021 May 19. pii: S1542-3565(21)00564.
    PubMed    


  292. CONSTANT BD, Dutmer CM, Arnold MA, Hall C, et al
    Cytotoxic T-Lymphocyte-Associated Antigen 4 Haploinsufficiency Mimics Difficult to Treat Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 May 6. pii: S1542-3565(21)00504.
    PubMed    


  293. CON D, Van Langenberg DR, Vasudevan A
    Response to: Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection.
    Clin Gastroenterol Hepatol. 2021;19:1077.
    PubMed    


  294. SAGAMI S, Kobayashi T, Miyatani Y, Okabayashi S, et al
    Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2021;19:908-921.
    PubMed     Abstract available


  295. BOSSUYT P, Dreesen E, Rimola J, Devuysere S, et al
    Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:947-954.
    PubMed     Abstract available


  296. SINGER AAM, Bloom DA, Adler J
    Factors Associated With Development of Perianal Fistulas in Pediatric Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:1071-1073.
    PubMed     Abstract available


    April 2021
  297. CON D, Vasudevan A, van Langenberg DR
    Predictive Scores in Acute Severe Ulcerative Colitis: Which, What and When are the Decision Points We Should Target?
    Clin Gastroenterol Hepatol. 2021 Apr 24. pii: S1542-3565(21)00469.
    PubMed    


  298. VOLGER S, Scherl E
    Biologics for Inflammatory Bowel Disease and their Safety in Pregnancy.
    Clin Gastroenterol Hepatol. 2021 Apr 14. pii: S1542-3565(21)00449.
    PubMed    


  299. ROTH K, Berinstein JA
    Reply: A Patient Perspective on Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021 Apr 8. pii: S1542-3565(21)00446.
    PubMed    


  300. BHATTACHARYA S, Marciano BE, Malech HL, Quezado M, et al
    Safety and efficacy of ustekinumab in the inflammatory bowel disease of chronic granulomatous disease.
    Clin Gastroenterol Hepatol. 2021 Apr 1. pii: S1542-3565(21)00349.
    PubMed    


  301. SORRENTINO D, Geraci M, Kuballa A
    Diagnosis of Preclinical Crohn's Disease: Hurdles, Challenges, and Hopes.
    Clin Gastroenterol Hepatol. 2021;19:857-858.
    PubMed    


  302. YZET C, Diouf M, Singh S, Brazier F, et al
    No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
    Clin Gastroenterol Hepatol. 2021;19:668-679.
    PubMed     Abstract available


  303. SIGALL BONEH R, Van Limbergen J, Wine E, Assa A, et al
    Dietary Therapies Induce Rapid Response and Remission in Pediatric Patients With Active Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:752-759.
    PubMed     Abstract available


  304. RIVIERE P, Vermeire S, Irles-Depe M, Van Assche G, et al
    Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies.
    Clin Gastroenterol Hepatol. 2021;19:713-720.
    PubMed     Abstract available


  305. JESSEN B, Rodriguez-Sillke Y, Sonnenberg E, Schumann M, et al
    Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab.
    Clin Gastroenterol Hepatol. 2021;19:721-731.
    PubMed     Abstract available


  306. BARNES EL, Kochar B, Herfarth HH, Winter RW, et al
    Creation of a Case-Finding Definition for Identifying Patients With Acute Pouchitis in Administrative Claims Data.
    Clin Gastroenterol Hepatol. 2021;19:842-844.
    PubMed     Abstract available


    March 2021
  307. AHMED W, Galati J, Kumar A, Christos PJ, et al
    Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Clin Gastroenterol Hepatol. 2021 Mar 30. pii: S1542-3565(21)00344.
    PubMed     Abstract available


  308. LOPES EW, Lebwohl B, Burke KE, Ivey KL, et al
    DIETARY GLUTEN INTAKE IS NOT ASSOCIATED WITH RISK OF INFLAMMATORY BOWEL DISEASE IN U.S. ADULTS WITHOUT CELIAC DISEASE.
    Clin Gastroenterol Hepatol. 2021 Mar 25. pii: S1542-3565(21)00339.
    PubMed     Abstract available


  309. DALAL RS, Esckilsen S, Barnes EL, Pruce JC, et al
    Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study.
    Clin Gastroenterol Hepatol. 2021 Mar 25. pii: S1542-3565(21)00338.
    PubMed    


  310. NAMBU R, Warner N, Mulder DJ, Kotlarz D, et al
    A Systematic Review of Monogenic Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Mar 18. pii: S1542-3565(21)00331.
    PubMed     Abstract available


  311. OKAMOTO T, Fukuda K
    Long-term outcomes in asymptomatic ulcerative colitis diagnosed during screening colonoscopy.
    Clin Gastroenterol Hepatol. 2021 Mar 11. pii: S1542-3565(21)00275.
    PubMed    


  312. SANDBORN WJ, Peyrin-Biroulet L, Sharara AI, Su C, et al
    Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
    Clin Gastroenterol Hepatol. 2021 Mar 5. pii: S1542-3565(21)00222.
    PubMed     Abstract available


  313. ALAMEEL T, Al Sulais E
    Risk of HBV Reactivation Among IBD patients With Occult Hepatitis B Virus Infection.
    Clin Gastroenterol Hepatol. 2021;19:621-622.
    PubMed    


  314. ANANTHAKRISHNAN AN, Deshpande V
    It Is All in the Fine Print: A Call for a Histopathology Checklist for IBD.
    Clin Gastroenterol Hepatol. 2021;19:446-447.
    PubMed    


  315. TANDON P, Malhi G, Abdali D, Pogue E, et al
    Active Margins, Plexitis, and Granulomas Increase Postoperative Crohn's Recurrence: Systematic Review and Meta-analysis.
    Clin Gastroenterol Hepatol. 2021;19:451-462.
    PubMed     Abstract available


  316. BORREN NZ, Plichta D, Joshi AD, Bonilla G, et al
    Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:519-527.
    PubMed     Abstract available


  317. SASSON AN, Ananthakrishnan AN, Raman M
    Diet in Treatment of Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:425-435.
    PubMed     Abstract available


    February 2021
  318. AKHTAR HJ, Nguyen TM, Ma C, Jairath V, et al
    Vedolizumab for the treatment of Non-Inflammatory Bowel Disease Related Enteropathy.
    Clin Gastroenterol Hepatol. 2021 Feb 19. pii: S1542-3565(21)00204.
    PubMed    


  319. JANGI S, Holmer AK, Dulai PS, Boland B, et al
    Spatial Evolution of Histologic and Endoscopic Healing in Left and Right Colon in Patients with Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021 Feb 5. pii: S1542-3565(21)00108.
    PubMed     Abstract available


  320. AKIYAMA S, Ollech JE, Rai V, Glick LR, et al
    Endoscopic phenotype of the J pouch in patients with inflammatory bowel disease: A new classification for pouch outcomes.
    Clin Gastroenterol Hepatol. 2021 Feb 4. pii: S1542-3565(21)00111.
    PubMed     Abstract available


  321. LONG MD, Siegel CA, Abraham BP, Chiorean M, et al
    Day Care Attendance and Infectious Complications in Children Born to Mothers with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2021 Feb 4. pii: S1542-3565(21)00104.
    PubMed    


  322. FALECK DM, Shmidt E, Huang R, Katta LG, et al
    Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.
    Clin Gastroenterol Hepatol. 2021;19:238-245.
    PubMed     Abstract available


  323. BOLAND K, Bedrani L, Turpin W, Kabakchiev B, et al
    Persistent Diarrhea in Patients With Crohn's Disease After Mucosal Healing Is Associated With Lower Diversity of the Intestinal Microbiome and Increased Dysbiosis.
    Clin Gastroenterol Hepatol. 2021;19:296-304.
    PubMed     Abstract available


  324. LANDEMAINE A, Petitcollin A, Brochard C, Miard C, et al
    Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection.
    Clin Gastroenterol Hepatol. 2021;19:288-295.
    PubMed     Abstract available


    January 2021
  325. LAURAIN PA, Guillo L, D'Amico F, Netter P, et al
    Incidence of and risk factors for colorectal strictures in ulcerative colitis: a multicenter study.
    Clin Gastroenterol Hepatol. 2021 Jan 22. pii: S1542-3565(21)00078.
    PubMed     Abstract available


  326. VAN DER SLOOT KWJ, Tiems JL, Visschedijk MC, Festen EAM, et al
    Cigarette smoke increases risk for colorectal neoplasia in inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2021 Jan 13. pii: S1542-3565(21)00018.
    PubMed     Abstract available


  327. DAI C, Huang YH, Jiang M
    Two Types of Fecal Tests in Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2021;19:209.
    PubMed    


  328. DEL HOYO J, Aguas M
    Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial.
    Clin Gastroenterol Hepatol. 2021;19:206-207.
    PubMed    


  329. BRENNER EJ, Kappelman MD
    Working Together to Meet the Needs of Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:210-211.
    PubMed    


  330. NAGANUMA M, Kanai T
    Reply.
    Clin Gastroenterol Hepatol. 2021;19:209-210.
    PubMed    


  331. LO CH, Khalili H, Song M, Lochhead P, et al
    Healthy Lifestyle Is Associated With Reduced Mortality in Patients With Inflammatory Bowel Diseases.
    Clin Gastroenterol Hepatol. 2021;19:87-95.
    PubMed     Abstract available


  332. OLLECH JE, Normatov I, Peleg N, Wang J, et al
    Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
    Clin Gastroenterol Hepatol. 2021;19:104-110.
    PubMed     Abstract available


  333. HANZEL J, Zdovc J, Kurent T, Sever N, et al
    Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.
    Clin Gastroenterol Hepatol. 2021;19:111-118.
    PubMed     Abstract available


    December 2020
  334. KIRCHGESNER J, Desai RJ, Beaugerie L, Schneeweiss S, et al
    Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease.
    Clin Gastroenterol Hepatol. 2020 Dec 30. pii: S1542-3565(20)31726.
    PubMed     Abstract available


  335. GUILLO L, Uzzan M, Beaugerie L, Gornet JM, et al
    Impact of HIV infection on the course of inflammatory bowel disease and drug safety profile: a multicenter GETAID study.
    Clin Gastroenterol Hepatol. 2020 Dec 24. pii: S1542-3565(20)31719.
    PubMed     Abstract available


  336. KHANNA R, Ma C, Jairath V, Casteele NV, et al
    Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials.
    Clin Gastroenterol Hepatol. 2020 Dec 15. pii: S1542-3565(20)31674.
    PubMed     Abstract available


  337. MA C, Jeyarajah J, Guizzetti L, Parker CE, et al
    Modeling Endoscopic Improvement after Induction Treatment with Mesalamine in Patients with Mild-to-Moderate Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Dec 3. pii: S1542-3565(20)31630.
    PubMed     Abstract available


    November 2020
  338. WANG CY, Chen WL, Cheng-Chung Wei J
    Link Between Inflammatory Bowel Disease and Risk of Chronic Kidney Disease.
    Clin Gastroenterol Hepatol. 2020 Nov 21. pii: S1542-3565(20)31498.
    PubMed    


  339. VAJRAVELU RK, Copelovitch L, Denburg MR
    Letter title: "Link between inflammatory bowel disease and risk of chronic kidney disease" by Wang and colleagues.
    Clin Gastroenterol Hepatol. 2020 Nov 20. pii: S1542-3565(20)31565.
    PubMed    


  340. BRAAT H, Parikh K, Peppelenbosch MP
    Complete Resolution of Mucosal Neutrophils May Predict Non-fatigue in Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Nov 19. pii: S1542-3565(20)31559.
    PubMed    


  341. GRACIE DJ, Ford AC
    Bugs and the Brain in Inflammatory Bowel Disease: A Novel Treatment Target?
    Clin Gastroenterol Hepatol. 2020 Nov 6. pii: S1542-3565(20)31434.
    PubMed    


  342. D'AMICO F, Danese S, Peyrin-Biroulet L
    Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.
    Clin Gastroenterol Hepatol. 2020;18:2689-2700.
    PubMed     Abstract available


    October 2020
  343. SANDBORN WJ, Peyrin-Biroulet L, Quirk D, Wang W, et al
    Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Oct 27. pii: S1542-3565(20)31496.
    PubMed     Abstract available


  344. TSAI L, Ma C, Dulai PS, Prokop LJ, et al
    Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-based Cohorts.
    Clin Gastroenterol Hepatol. 2020 Oct 27. pii: S1542-3565(20)31497.
    PubMed     Abstract available


  345. OLLECH JE, Avni-Biron I, Glick L, Haider H, et al
    Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated with Good Maternal and Fetal Outcomes.
    Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31493.
    PubMed     Abstract available


  346. LI YM, Stettler I, Oungpasuk K
    Association Between Provider Connectedness and Inflammatory Bowel Disease Outcomes.
    Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31291.
    PubMed    


  347. STEENHOLDT C, Jensen JT, Brynskov J, Moller AM, et al
    Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31495.
    PubMed     Abstract available


  348. VEDAMURTHY A, Gangasani N, Ananthakrishnan AN
    Vedolizumab or TNF-antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: A retrospective cohort study.
    Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31396.
    PubMed     Abstract available


  349. KHOUDARI G, Mansoor E, Click B, Alkhayyat M, et al
    Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients after Initiation of Biologics: A Cohort Study.
    Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31397.
    PubMed     Abstract available


  350. NAESSENS D, Cameron C, Hoaglin DC
    Network Meta-Analysis of Ulcerative Colitis Pharmacotherapies: Carryover Effects from Induction and Bias of the Results.
    Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31428.
    PubMed    


  351. BRENNER EJ, Pigneur B, Focht G, Zhang X, et al
    BENIGN EVOLUTION OF SARS-CoV2 INFECTIONS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM TWO INTERNATIONAL DATABASES.
    Clin Gastroenterol Hepatol. 2020 Oct 12. pii: S1542-3565(20)31399.
    PubMed    


  352. COLOMBEL JF, Osterman MT, Thorpe AJ, Salese L, et al
    Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Oct 8. pii: S1542-3565(20)31389.
    PubMed     Abstract available


  353. LUKIN D, Faleck D, Xu R, Zhang Y, et al
    Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Oct 8. pii: S1542-3565(20)31388.
    PubMed     Abstract available


    September 2020
  354. KIM HJ, Shah SC, Hann HJ, Kazmi SZ, et al
    Familial Risk of Inflammatory Bowel Disease - A Population-based Cohort study in South Korea.
    Clin Gastroenterol Hepatol. 2020 Sep 30. pii: S1542-3565(20)31384.
    PubMed     Abstract available


  355. DIMKE H, Winther-Jensen M, Allin KH, Lund L, et al
    Risk of Urolithiasis in Patients with Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Sep 29. pii: S1542-3565(20)31379.
    PubMed     Abstract available


    August 2020
  356. STORAN D, Doherty GA, Cullen G
    Ustekinumab 90 mg Every 2 Weeks for the Treatment of Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Aug 30. pii: S1542-3565(20)31079.
    PubMed    


  357. GILMORE R, Hilley P, Srinivasan A, Choy MC, et al
    Tofacitinib is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Aug 16. pii: S1542-3565(20)31008.
    PubMed    


  358. BERINSTEIN JA, Steiner CA, Higgins PDR
    Reply to Tofacitinib is safe and effective when used in combination with Infliximab for the management of Refractory Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2020 Aug 12. pii: S1542-3565(20)31132.
    PubMed    


    July 2020
  359. AREBI N, Dyall L, Kamperidis N
    A User's Guide to De-Escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Jul 27. pii: S1542-3565(20)30920.
    PubMed    


    June 2020
  360. SCAIOLI E, Salice M, Belluzzi A
    Omega-3 as a Part of the Dietary Guidance for Patients with Ulcerative Colitis: Beyond the Natural Sources.
    Clin Gastroenterol Hepatol. 2020 Jun 25. pii: S1542-3565(20)30760.
    PubMed    


  361. PAPAMICHAEL K, Cheifetz AS
    Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
    Clin Gastroenterol Hepatol. 2020 Jun 5. pii: S1542-3565(20)30638.
    PubMed    


    April 2020
  362. ONA S, Long M, Mitchell C
    Reply.
    Clin Gastroenterol Hepatol. 2020;18:1002.
    PubMed    


    February 2020
  363. PANSART C, Roblin X, Paul S
    Preanalytical Heterogeneity in Fecal Calprotectin Measurement Needs To Be Considered for Tight Control.
    Clin Gastroenterol Hepatol. 2020;18:524-525.
    PubMed    


  364. KENNEDY NA, Lees CW
    Reply.
    Clin Gastroenterol Hepatol. 2020;18:526.
    PubMed    


  365. COZIJNSEN MA, Turner D
    Reply.
    Clin Gastroenterol Hepatol. 2020;18:525-526.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.